Immunochemical Prophylaxis against Pseudomonas aeruginosa

  • Michael S. Collins
Part of the Infectious Agents and Pathogenesis book series (IAPA)

Abstract

Healthy people are rarely infected by Pseudomonas aeruginosa. Consequently, serious P. aeruginosa infections are rarely community-acquired. However, in the hospital setting, P. aeruginosa causes about 7–15% of life-threatening bacterial infections such as bacteremia and pneumonia.1–5 In cystic fibrosis (CF), P. aeruginosa is the predominant pathogen.6,7P. aeruginosa merits special attention as a common bacterial nosocomial pathogen, for the mortality rate is significantly higher than that seen in infections caused by other common gram-negative bacilli and staphylococci.8–10 Thus, in the host compromised by extreme youth or age, trauma, cancer, immunosuppressive therapy, or mechanical ventilation, P. aeruginosa can be a highly virulent pathogen.1,2,8–10 In the compromised patient P. aeruginosa has several attributes that contribute to its high virulence. P. aeruginosa is innately less sensitive than other common gram-negative bacilli to modern antimicrobials such as semisynthetic penicillins, third-generation cephalosporins, aminoglycosides, and fluorinated carboxyquinolones.11–15 Resistance can emerge during anti-microbial therapy, resulting in treatment failure.16–20 Also, it is insensitive to frequently used agents such as trimethoprim-sulfamethoxazole, tetracycline, ampicillin, and first-and second-generation cephalosporins. The use of theselatter oral antimicrobials for infection prophylaxis profoundly alters normal flora and can promote colonization of the host.21–23

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bennett, J. V., 1974, Nosocomial infections due to Pseudomonas, J. Infect. Dis. 130:S4—S7.PubMedCrossRefGoogle Scholar
  2. 2.
    Tapper, M. L., and Armstrong, D., 1974, Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: A progress report, J. Infect. Dis. 130:S14–23.PubMedCrossRefGoogle Scholar
  3. 3.
    Baltch, A. A., and Smith, R. P., 1985, Combinations of antibiotics against Pseudomonas aeruginosa, Am. J. Med. 79:8–16.PubMedCrossRefGoogle Scholar
  4. 4.
    Bisbe, J., Gate11, J. M., Puig, J., Mallolas, J., Martinez, J. A., Jimenez de Anta, M. T., and Soriano, E., 1988, Pseudomonas aeruginosa bacteremia: Univariate and multivarate analyses of factors influencing the prognosis in 133 episodes, Rev. Infect. Dis. 10:629–635.PubMedCrossRefGoogle Scholar
  5. 5.
    Kato, M., de la Vega, S. L., and Mohar, A., 1990, Infections in patients with cancer in Mexico, Rev. Infect. Dis. 12:960–961.PubMedCrossRefGoogle Scholar
  6. 6.
    May, J. R., Herrick, N. C., and Thompson, D., 1972, Bacterial infection in cystic fibrosis, Arch. Dis. Child. 47:903–913.CrossRefGoogle Scholar
  7. 7.
    Mearns, M. B., Hunt, G. H., and Rushworth, R., 1972, Bacterial flora of the respiratory tract in patients with cystic fibrosis, Arch. Dis. Child. 47:902–907.PubMedCrossRefGoogle Scholar
  8. 8.
    Bryan, C. S., and Reynolds, K. L., 1984, Bacteremic nosocomial pneumonia. Analysis of 172 episodes from a single metropolitan area, Am. Rev. Respir. Dis. 135:426–432.Google Scholar
  9. 9.
    Craig, C. P., and Connelly, S., 1984, Effect of intensive care unit nosocomial pneumonia on duration of stay and mortality, Infect. Control 12:233–238.CrossRefGoogle Scholar
  10. 10.
    McManus, A. T., Mason, A. D., Jr., McManus, W. E, and Pruitt, B. A., Jr., 1985, Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center, Eur. J. Clin. Microbiol. 4: 219–223.PubMedCrossRefGoogle Scholar
  11. 11.
    Eickhoff, T. C., and Ehret, J. M., 1976, In vitro comparison of cefoxitin, cefamandole, cephalexin and cephalothin, Antimicrob. Agents Chemother. 9:994–999.PubMedCrossRefGoogle Scholar
  12. 12.
    Reimer, L. G., Stratton, C. W, and Relier, L. B., 1981, Minimum inhibitory and bactericidal concentrations of 44 antimicrobial agents against three standard control strains in broth with and without human serum, Antimicrob. Agents Chemother. 19:1050–1055.PubMedCrossRefGoogle Scholar
  13. 13.
    Digranes, A., Dibb, W. L., and Østervold, B., 1984, In vitro comparison of the activity to five ß-lactam antibiotics and gentamicin against 493 clinical, bacterial isolates: A Norwegian study, Curr. Ther. Res. 35:610–617.Google Scholar
  14. 14.
    Parry, M. E, Folta, D., Nossek, H., Anderson, M., Azzarello, L., Holmes, D., Jacob, R., McElree, S., Sabato, S., Tatton, B., and Welch, B., 1985, Comparative activity of ciprofloxacin and other new agents against 1454 clinical isolates at a community hospital, Curr. Ther. Res. 38:755–761.Google Scholar
  15. 15.
    Satta, G., Cornaglia, G., Foddis, G., and Pompei, R., 1988, Evaluation of ceftriaxone and other antibiotics against Escherichia coli, Pseudomonas aeruginosa, and Streptococcus pneumoniae under in vitro conditions simulating those of serious infections, Antimicrob. Agents Chemother. 32:552–560.CrossRefGoogle Scholar
  16. 16.
    Schimpff, S. C., Greene, W. H., Young, V. M., and Wiernik, P. H., 1974, Significance of Pseudomonas aeruginosa in the patient with leukemia or lymphoma, J. Infect. Dis. 130: S24–S31.PubMedCrossRefGoogle Scholar
  17. 17.
    Mathisen, G. E., Meyer, R. D., Thompson, J. M., and Finegold, S. M., 1982, Clinical evaluation of moxalactam, Antimicrob. Agents Chemother. 21:780–786.PubMedCrossRefGoogle Scholar
  18. 18.
    Bayer, A. S., Hirano, L., and Yih, J., 1988, Development of β-lactam resistance and increased quinoline MICs during therapy of experimental Pseudomonas aeruginosa endocarditis, Antimicrob. Agents Chemother. 32:231–235.PubMedCrossRefGoogle Scholar
  19. 19.
    Milatovic, D., and Bravery, I., 1987, Development of resistance during antibiotic therapy, Eur. J Clin. Microbiol. 6:234–244.PubMedCrossRefGoogle Scholar
  20. 20.
    LeBel, M., Bergeron, M. G., Vallee, E, Fiset, C., Chasse, G., Bigonesse, P, and Rivard, G., 1986, Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients, Antimicrob. Agents Chemother. 30:260–266.PubMedCrossRefGoogle Scholar
  21. 21.
    Shooter, R. A., Walker, K. A., Williams, V. R., Horgan, G. M., Parker, M. T., Asheshov, E. H., and Bullimore, J., 1966, Faecal carriage of Pseudomonas aeruginosa in hospital patients. Possible spread from patient to patient, Lancet 2:1331–1334.PubMedCrossRefGoogle Scholar
  22. 22.
    Bauernfiend, A., Emminger, G., Hörl, G., Lorbeer, B., Przyklenk, B., and Weisslein-Pfister, C., 1987, Selective pressure of antistaphylococcal chemotherapeutics in favor of Pseudomonas aeruginosa in cystic fibrosis, Infection 15:469–470.CrossRefGoogle Scholar
  23. 23.
    Griffith, S. J., Nathan, C., Selander, R. K., Chamberlin, W, Gordon, S., Kabins, S., and Weinstein, R. A., 1989, The epidemiology of Pseudomonas aeruginosa in oncology patients in a general hospital, J. Infect. Dis. 160:1030–1036.PubMedCrossRefGoogle Scholar
  24. 24.
    Bodey, G. P., Bolivar, R., Fainstein, V., and Jadeja, L., 1983, Infections caused by Pseudomonas aeruginosa, Rev. Infect. Dis. 5:279–313.PubMedCrossRefGoogle Scholar
  25. 25.
    Grogan, J. B., 1966, Pseudomonas aeruginosa carriage in patients, J. Trauma 6:639–643.PubMedCrossRefGoogle Scholar
  26. 26.
    Schimpff, S. C., Moody, M., and Young, V. M., 1970, Relationship of colonization with Pseudomonas aeruginosa to development of Pseudomonas bacteremia in cancer patients, Antimicrob. Agents Chemother. 10:240–244.PubMedGoogle Scholar
  27. 27.
    Janda, J. M., and Bottone, E. J., 1981, Pseudomonas aeruginosa enzyme profiling: Predictor of potential invasiveness and use as an epidemiological tool, J. Clin. Microbiol. 14:55–60.PubMedGoogle Scholar
  28. 28.
    Cash, H. A., Straus, D. C., and Bass, J. A., 1983, Pseudomonas aeruginosa exoproducts as pulmonary virulence factors, Can. J. Microbiol. 29:448–456.PubMedCrossRefGoogle Scholar
  29. 29.
    Nicas, T. I., and Iglewski, B. H., 1985, The contribution of exoproducts of virulence of Pseudomonas aeruginosa, Can. J. Microbiol. 31:387–392.PubMedCrossRefGoogle Scholar
  30. 30.
    Gessard, C., 1982, Sur les colorations bleue et verte des linges a pansements, Compt. Rend. Acad. Sci. 94:536–568.Google Scholar
  31. 31.
    Curtin, J. A., Petersdorf, R. J., and Bennett, I. L., Jr., 1961, Pseudomonas bacteremia: Review of ninety-one cases, Ann. Intern. Med. 54:1077–1107.Google Scholar
  32. 32.
    Davis, S. D., Iannette, A., and Wedgwood, R. J., 1971, Antibiotics for Pseudomonas aeruginosa sepsis: Inadequate proof of efficacy, J. Infect. Dis. 124:104–106.PubMedCrossRefGoogle Scholar
  33. 33.
    Baltch, A. L., and Griffin, P. E., 1977, Pseudomonas aeruginosa: A clinical study of 75 patients, Am. J Med. Sci. 247:119–129.CrossRefGoogle Scholar
  34. 34.
    Baltch, A. L., Hammer, M., Smith, R. P, and Stuphen, N., 1979, Pseudomonas aeruginosa bacteremia. Susceptibility of 100 blood culture isolates to given antimicrobial agents and its clinical significance, J. Lab. Clin. Med. 94:201–214.PubMedGoogle Scholar
  35. 35.
    Millican, C., Evans, G., and Markley, K., 1966, Susceptibility of burned mice to Pseudomonas aeruginosa and protection by vaccination, Ann. Surg. 163:603–610.PubMedCrossRefGoogle Scholar
  36. 36.
    Markley, K., and Smallman, E., 1968, Protection by vaccination against Pseudomonas infection after thermal injury, J. Bacterial. 96:867–874.Google Scholar
  37. 37.
    Jones, R. J., 1968, Protection against Pseudomonas aeruginosa infection by immunization with fractions of culture filtrates of P. aeruginosa, Br. J Exp. Pathol. 49:411–420.PubMedGoogle Scholar
  38. 38.
    Jones, R. J., 1972, Specificity of early protective responses induced by Pseudomonas vaccines, J. Hyg. 70:343–351.CrossRefGoogle Scholar
  39. 39.
    Miller, J. M., Spilsbury, J. E, Jones, R. J., Roe, E. A., and Lowbury, E. J. L., 1976, A new polyvalent Pseudomonas vaccine, J. Med. Microbiol. 10:19–27.CrossRefGoogle Scholar
  40. 40.
    Jones, R. J., Roe, E. A., and Gupta, J. L., 1978, Low mortality in burned patients in a Pseudomonas vaccine trial, Lancet ii:401–403.CrossRefGoogle Scholar
  41. 41.
    MacIntyre, S., McVeigh, T., and Owen, P., 1986, Immunochemical and biochemical analysis of the polyvalent Pseudomonas aeruginosa vaccine PEV, Infect. Immun. 51:675–686.PubMedGoogle Scholar
  42. 42.
    MacIntyre, S., Lucken, R., and Owen, P., 1986, Smooth lipopolysaccharide is the major protective antigen for mice in the surface extract from IATS serotype 6 contributing to the polyvalent Pseudomonas aeruginosa vaccine PEV, Infect. Immun. 52:76–84.PubMedGoogle Scholar
  43. 43.
    Brokopp, C. D., Gomez-Lus, R., and Farmer, J. J., III, 1977, Serological typing of Pseudomonas aeruginosa: Use of commercial antisera and live antigens, J. Clin. Microbiol. 5: 640–649.PubMedGoogle Scholar
  44. 44.
    Fisher, M. W., Devlin, H. B., and Gnabasik, E J., 1969, New immunotype schema for Pseudomonas aeruginosa based on protective antigens, J. Bacteriol. 98:835–836.PubMedGoogle Scholar
  45. 45.
    Verder, E., and Evans, J. A., 1961, A proposed antigenic schema for the identification of strains of Pseudomonas aeruginosa, J Infect. Dis. 109:183–193.PubMedCrossRefGoogle Scholar
  46. 46.
    Hanessian, S., Regan, W., Watson, D., and Haskell, T. H., 1971, Isolation and characterization of antigenic components of a new heptavalent Pseudomonas vaccine, Nature 229: 209–210.Google Scholar
  47. 47.
    Young, L. S., Meyer, R. D., and Armstrong, D., 1973, Pseudomonas aeruginosa vaccine in cancer patients, Ann. Intern. Med. 79:518–527.PubMedGoogle Scholar
  48. 48.
    Pennington, J. E., 1974, Preliminary investigation of Pseudomonas aeruginosa vaccine in patients with leukemia and cystic fibrosis, J. Infect. Dis. 130:S159—S162.PubMedCrossRefGoogle Scholar
  49. 49.
    Harvath, L., and Andersen, B. R., 1976, Evaluation of type-specific and non-type specific Pseudomonas vaccine for treatment of Pseudomonas sepsis during granulocytopenia, Infect. Immun. 13:1139–1143.PubMedGoogle Scholar
  50. 50.
    Drewry, D. J., Symes, K. C., Gray, G. W., and Wilkinson, S. G., 1975, Studies of polysaccharide fractions from the lipopolysaccharide of Pseudomonas aeruginosa N.C.T.C. 1999, Biochem J. 149:93–106.Google Scholar
  51. 51.
    Tsay, G. C., and Collins, M. S., 1984, Preparation and characterization of a nontoxic polysaccharide-protein conjugate that induces active immunity and passively protective antibody against Pseudomonas aeruginosa immunotype 1 in mice, Infect. Immun. 45:217–221.PubMedGoogle Scholar
  52. 52.
    Cryz, S. J., Jr., Fürer, E., Sadoff, J. C., and Germanier, R., 1986, Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine, Infect. Immun. 52:161–165.PubMedGoogle Scholar
  53. 53.
    Cryz, S. J., Jr., Fürer, E., Cross, A. S., Wegmann, A., Germanier, R., and Sadoff, J. C., 1987, Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine in humans, J Clin. Invest. 80:51–56.PubMedCrossRefGoogle Scholar
  54. 54.
    Cryz, S. J., Jr., Fürer, E., Sadoff, J. C., and Germanier, R., 1987, A polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine, Antibiot. Chemother. 39:249–255.PubMedGoogle Scholar
  55. 55.
    Cryz, S. J., Sadoff, J. C., Cross, A. S., and Fürer, E., 1989, Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A vaccine in humans, Antibiot. Chemother. 42:177–183.PubMedGoogle Scholar
  56. 56.
    Cryz, S. J., Jr., Fürer, E., Sadoff, J. C., Fredking, T., Que, J. U., and Cross, A. S., 1991, Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species, J Infect. Dis. 163:1055–1061.PubMedCrossRefGoogle Scholar
  57. 57.
    Pier, G. B., Sidberry, H. E, Zolyomi, S., and Sadoff, J. C., 1978, Isolation and characterization of a high-molecular weight polysaccharide from the slime of Pseudomonas aeruginosa, Infect. Immun. 22:908–918.PubMedGoogle Scholar
  58. 58.
    Pier, G. B., Sidberry, H. E, and Sadoff, J. C., 1981, High-molecular weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2, Infect. Immun. 34:461–468.PubMedGoogle Scholar
  59. 59.
    Pier, G. B., and Thomas, D. M., 1983, Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa, J. Infect. Dis. 148:206–213.PubMedCrossRefGoogle Scholar
  60. 60.
    Cryz, S. J., Jr., Fürer, E., and Germanier, R., 1984, Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high molecular weight polysaccharide, Infect. Immun. 43:795–799.PubMedGoogle Scholar
  61. 61.
    Lam, J. S., Mutharia, L. M., Hancock, R. E. W, Holby, N., Lam, K., Baek, L., and Costerton, J. W, 1983, Immunogenicity of Pseudomonas aeruginosa outer membrane antigens examined by crossed immunoelectrophoresis, Infect. Immun. 42:88–98.PubMedGoogle Scholar
  62. 62.
    Matthews-Greer, J. M., and Gilleland, H. E., Jr., 1987, Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model, J Infect. Dis. 155:1281–1291.CrossRefGoogle Scholar
  63. 63.
    Gilleland, H. E., Jr., and Matthews-Greer, J. M., 1987, Perspectives on the potential for successful development of outer membrane protein vaccines, Eur. j Clin. Microbiol. 6:231–233.PubMedCrossRefGoogle Scholar
  64. 64.
    Garner, C. V, Desjardins, D., and Pier, G. B., 1990, Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide, Infect. Immun. 58:1835–1842.PubMedGoogle Scholar
  65. 65.
    Pier, G. B., Small, G. J., and Warren, H. B., 1990, Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infection, Science 249:537–540.PubMedCrossRefGoogle Scholar
  66. 66.
    Montie, T. C., Drake, D., Sellin, H., Slater, O., and Edmonds, S., 1987, Motility, virulence and protection with a flagella vaccine against Pseudomonas aeruginosa infection, Antibiot. Chemother. 39:233–248.PubMedGoogle Scholar
  67. 67.
    Holder, I. A., Wheeler, R., and Monde, T. C., 1982, Flagellar preparations from Pseudomonas aeruginosa: Animal protection studies, Infect. Immun. 35:276–280.PubMedGoogle Scholar
  68. 68.
    Holder, I. A., and Naglich, J. G., 1986, Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: Immunization using divalent flagella preparations, J Trauma 26:118–122.PubMedCrossRefGoogle Scholar
  69. 69.
    Rotering, H., and Dorner, E, 1989, Studies on a Pseudomonas aeruginosa flagella vaccine, Antibiot. Chemother. 42:218–228.PubMedGoogle Scholar
  70. 70.
    Sezen, I. Y., Scharmann, W, and Blobel, H., 1975, Effects of an antiserum prepared against purified protease of Pseudomonas aeruginosa, Zentralbl. Bakteriol. Hyg. I. Abt. Orig. 231: 126–132.Google Scholar
  71. 71.
    Cryz, S. J., Jr., Fürer, E., and Germanier, R., 1983, Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model, Infect. Immun. 40: 659–664.PubMedGoogle Scholar
  72. 72.
    Cryz, S. J., Jr., Fürer, E., and Germanier, R., 1983, Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase and antilipopolysaccharide, Infect. Immun. 39:1072–1079.PubMedGoogle Scholar
  73. 73.
    Lydick, E., McLean, A. A., Woodhour, A. E, and Callahan, L. T., III., 1985, Responses of adult volunteers to a Pseudomonas aeruginosa exotoxoid-A vaccine, J Infect. Dis. 151:375.PubMedCrossRefGoogle Scholar
  74. 74.
    Chong, K. T, and Huston, M., 1987, Implications of endotoxin contamination in the evaluation of antibodies to lipopolysaccharide in a murine model of gram-negative sepsis, J. Infect. Dis. 156:713–719.PubMedCrossRefGoogle Scholar
  75. 75.
    Marx, A., Meitert, E., Salageanu, A., Olinescu, A., Savulian, C., Sima, E, and Chersulick, E., 1987, Specific and nonspecific protection of mice by Pseudomonas aeruginosa lipopolysaccharides, Zentralbl. Bakteriol. Hyg. A. 264:154–162.Google Scholar
  76. 76.
    Lányi, B., 1970, Serological properties of Pseudomonas aeruginosa II. Type-specific thermolabile (flagellar) antigens, Acta Microbial. Acad. Hung. 17:35–48.Google Scholar
  77. 77.
    Ansorg, R. A., Knoche, M. E., Spries, A. E, and Kraus, C. J., 1984, Differentiation of the major flagellar antigens of Pseudomonas aeruginosa by the slide coagglutination technique, J.Clin. Microbial. 20:84–88.Google Scholar
  78. 78.
    McManus, A. T., Moody, E. E., and Mason, A. D., 1980, Bacterial motility: A component in experimental Pseudomonas aeruginosa burn wound sepsis, Burns 6:235–239.CrossRefGoogle Scholar
  79. 79.
    Craven, R. A., and Montie, T. C., 1981, Motility and chemotaxis of three strains of Pseudomonas aeruginosa used for virulence studies, Can. J. Microbial. 27:458–460.CrossRefGoogle Scholar
  80. 80.
    Drake, D., and Montie, T. C., 1988, Flagella, motility and invasive virulence of Pseudomonas aeruginosa, J. Gen. Microbial. 134:43–52.Google Scholar
  81. 81.
    Allison, J. S., Dawson, M., Drake, D., and Monde, T. C., 1985, Electrophoretic separation and molecular weight characterization of Pseudomonas aeruginosa H-antigen flagillins, Infect. Immun. 49:770–774.PubMedGoogle Scholar
  82. 82.
    Ansorg, R., 1978, Flagellaspezifisches H-antigenschema von Pseudomonas aeruginosa, Zentralbl. iol. Mikrobiol. Hyg. [A] 242:228–238.Google Scholar
  83. 83.
    Anderson, T. R., and Montie, T. C., 1987, Opsonophagocytosis of Pseudomonas aeruginosa treated with antiflagellar serum, Infect. Immun. 55:3204–3206.PubMedGoogle Scholar
  84. 84.
    Montie, T. C., Craven, R. C., and Holder, I. A., 1982, Flagellar preparations from Pseudomonas aeruginosa: Isolation and characterization, Infect. Immun. 35:281–288.PubMedGoogle Scholar
  85. 85.
    Ansorg, R., Schmitt, W, and Schwerk, V., 1978, Antikörperbildung gegen somatische und flagelläre Antigene von Pseudomonas aeruginosa, Med. Microbiol. Immunol. 165:181–189.PubMedCrossRefGoogle Scholar
  86. 86.
    Moody, M. R., Kessel, R. W. I., Young, V. M., and Fiset, E, 1978, Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infection, Infect. Immun. 21:905–913.PubMedGoogle Scholar
  87. 87.
    Harmon, R. C., Rutherford, R. L., Wu, H. M., and Collins, M. S., 1989, Monoclonal antibody-mediated protection and neutralization of motility in experimental Proteus mirabilis infection, Infect. Immun. 57:1936–1941.PubMedGoogle Scholar
  88. 88.
    Heidbrink, P. J., Toews, G. B., Gross, G. N., and Pierce, A. K., 1982, Mechanisms of complement-mediated clearance of bacteria from the murine lung, Am. Rev. Respir. Dis. 125:517–520.PubMedGoogle Scholar
  89. 89.
    Cerquetti, M. C., Sordelli, D. O., Bellanti, J. A., and Hooke, A. M., 1986, Lung defenses against Pseudomonas aeruginosa in C5-deficient mice with different genetic backgrounds, Infect. Immun. 52:853–857.PubMedGoogle Scholar
  90. 90.
    Young, L. S., and Armstrong, D., 1972, Human immunity to Pseudomonas aeruginosa I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors, J. Infect. Dis. 126:257–276.PubMedCrossRefGoogle Scholar
  91. 91.
    Bjornson, A. B., and Michael, J. G., 1971, Contribution of humoral and cellular factors to the resistance of experimental infection by Pseudomonas aeruginosa in mice I. Interaction between immunoglobulins, heat labile serum factors, and phagocytic cells in the killing of bacteria, Infect. Immun. 4:462–467.PubMedGoogle Scholar
  92. 92.
    Bjornson, A. B., and Michael, J. G., 1972, Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice, II. Opsonic, agglutinative and protective capacities of immunoglobulin G anti-Pseudomonas antibodies, Infect. Immun. 5:775–782.PubMedGoogle Scholar
  93. 93.
    Epstein, R. B., Wayman, E. J., Bennett, B. T., and Anderson, B. R., 1974, Pseudomonas septicemia in neutropenic dogs 1. Treatment with granulocyte transfusions, Transfusion 14: 51–57.PubMedCrossRefGoogle Scholar
  94. 94.
    Strauss, R. G., 1978, Therapeutic neutrophil transfusions: Are controlled studies no longer appropriate? Am. J. Med. 65:1001–1006.PubMedCrossRefGoogle Scholar
  95. 95.
    Winston, D. J., Ho, W. G., Howell, C. L., Miller, M. J., Mickey, R., Martin, W. J., Lin, C. -H., and Gale, R. P., 1980, Cytomegalovirus infections associated with leukocyte transfusions, Ann. Intern. Med. 93:671–675.PubMedGoogle Scholar
  96. 96.
    Tanaka, T., Okamura, S., Okada, K., Suga, A., Shimono, N., Ohhara, N., Yoshio, H., Sawae, Y., and Niho, Y., 1989, Protective effect of recombinant murine granulocyte-macrophage colony-stimulating factor against Pseudomonas aeruginosa infection in leukopenic mice, Infect. Immun. 57:1792–1799.PubMedGoogle Scholar
  97. 97.
    Cohn, E. J., Strong, L. E., Hughes, W. C., Jr., Mulford, D. J., Ashworth, J. N., Melin, M., and Taylor, H. L., 1946, Preparation and properties of serum and plasma proteins IV. A system for the separation into fractions and lipoprotein components of biological tissue and fluids, J Am. Chem. Soc. 68:459–475.PubMedCrossRefGoogle Scholar
  98. 98.
    Pollack, M., 1983, Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans, J. Infect. Dis. 147:1090–1098.PubMedCrossRefGoogle Scholar
  99. 99.
    Rosenthal, S. M., 1967, Local and systemic therapy of Pseudomonas septicemia in burned mice, Ann. Surg. 165:97–103.PubMedCrossRefGoogle Scholar
  100. 100.
    Fisher, M. W, and Manning, M. C., 1958, Studies on the immunotherapy of bacterial infections: I. The comparative effectiveness of human ry-globulin against various bacterial species in mice, J. Immunol. 81:29–31.PubMedGoogle Scholar
  101. 101.
    Waisbren, B. A., 1957, The treatment of bacterial infections with the combination of antibiotics and gamma globulin, Antibiot. Chemother. 7:322–333.Google Scholar
  102. 102.
    Fisher, M. W, 1957, Synergism between human gamma globulin and chloramphenicol in the treatment of experimental bacterial infections, Antibiot. Chemother. 7:315–321.Google Scholar
  103. 103.
    Milican, R. C., Rust, J., and Rosenthal, S. M., 1957, Gamma globulin factors protective against infections from Pseudomonas and other organisms, Science 126:509–511.CrossRefGoogle Scholar
  104. 104.
    Stone, H. H., Graber, C. D., Martin, J. D., Jr., and Kolb, L., 1965, Evaluation of gamma globulin for prophylaxis against burn sepsis, Surgery 58:810–814.PubMedGoogle Scholar
  105. 105.
    Kefalides, N. A., Arana, J. A., Bazan, A., Bocanegra, M., Stastry, P., Velarde, N., and Rosenthal, S. M., 1962, Role of infection in mortality from severe burns: Evaluation of plasma, gamma-globulin, albumin and saline-solution therapy in a group of Peruvian children, N. Engl. J. Med. 267:317–323.PubMedCrossRefGoogle Scholar
  106. 106.
    Barandun, S., Kistler, P., Jeunet, E, and Isliker, H., 1962, Intravenous administration of human γ-globulin, Vox Sang. 7:157–174.PubMedCrossRefGoogle Scholar
  107. 107.
    Smith, G. N., Griffiths, B., Mollison, D., and Mollison, P. L., 1972, Uptake of IgG after intramuscular and subcutaneous injection, Lancet 2:1208–1212.CrossRefGoogle Scholar
  108. 108.
    Ceska, M., 1981, Binding of protein A to some human gamma-globulins used intravenously, Vox Sang. 40:395–402.PubMedCrossRefGoogle Scholar
  109. 109.
    Skvaril, F., and Gardi, A., 1988, Difference among available immunoglobulin preparations for intravenous use, Pediatr. Infect. Dis. J. 7:S43–S48.PubMedCrossRefGoogle Scholar
  110. 110.
    Steele, R. W, and Steele, R. W, 1989, Functional capacity of immunoglobulin G preparations and the F(ab)2 split product, J. Clin. Microbiol. 27:640–643.PubMedGoogle Scholar
  111. 111.
    Lundblad, J. L., Mitra, G., Sternberg, M. M., and Schroeder, D. D., 1986, Comparative studies of impurities in intravenous immunoglobulin preparations, Rev. Infect. Dis. 8:S382–S390.PubMedCrossRefGoogle Scholar
  112. 112.
    Greenbaum, B. H., 1990, Differences in immunoglobulin preparations for intravenous use: A comparison of six products, J. Pediair. Hematol. Oncol. 12:490–496.CrossRefGoogle Scholar
  113. 113.
    Davis, S. D., 1975, Efficacy of modified human immun serum globulin in the treatment of experimental murine infections with seven immunotypes of Pseudomonas aeruginosa, J. Infect. Dis. 131:717–721.PubMedCrossRefGoogle Scholar
  114. 114.
    Hill, H. R., and Bathras, J. M., 1986, Protective and opsonic activities of a native pH 4.25 intravenous immunoglobulin G preparation against common bacterial pathogens, Rev. Infect. Dis. 8:S396–S400.PubMedCrossRefGoogle Scholar
  115. 115.
    Hill, H. R., Augustine, N. H., and Shigeoka, A. 0., 1984, Comparative opsonic activity of intravenous gamma globulin preparations for common bacterial pathogens, Am. J. Med. 76: 61–66.PubMedCrossRefGoogle Scholar
  116. 116.
    Tomioka, H., Iwamura, Y., Suzuki, Y., Ohtomo, S., and Hashimoto, Y., 1980, Protective effects of S-sulfonated human gamma globulin against experimental infections in mice, Infect. Immun. 30:329–336.PubMedGoogle Scholar
  117. 117.
    Jupa-Marcinkowski, V, Mynard, M. C., Danve, B., and Schmitz, P. I. M., 1985, The influence of immunoglobulin on the development of Pseudomonas aeruginosa infection in an immunocompromised mouse model, J. Biol. Stand. 13:235–242.PubMedCrossRefGoogle Scholar
  118. 118.
    Collins, M. S., and Roby, R. E., 1983, Anti-Pseudomonas aeruginosa activity of an intravenous human IgG preparation in burned mice, J. Trauma 23:530–534.PubMedCrossRefGoogle Scholar
  119. 119.
    Collins, M. S., and Dorsey, J. H., 1984, Comparative anti-Pseudomonas aeruginosa activity of chemically modified and native immunoglobulin G (human) and potentiation of antibiotic protection against Pseudomonas aeruginosa and group B Streptococcus in vivo, Am. J. Med. 76: 155–160.PubMedCrossRefGoogle Scholar
  120. 120.
    Holder, I. A., and Naglich, J. G., 1984, Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: Treatment with intravenous immunoglobulin. Am. J. Med. 76:161–167.PubMedCrossRefGoogle Scholar
  121. 121.
    Collins, M. S., Tsay, G. C., Hector, R. E, Roby, R. E., and Dorsey, J. H., 1986, Immunoglobulin G: Potentiation of tobramycin and azlocillin in the treatment of Pseudomonas aeruginosa sepsis in neutropenic mice and neutralization of exotoxin A in vivo, Rev. Infect. Dis. 8:S420–S425.PubMedCrossRefGoogle Scholar
  122. 122.
    Moody, M. R., Young, V. M., Kemton, D. M., and Vermeulen, G. D., 1972, Pseudomonas aeruginosa in a center for cancer research. I. Distribution of intraspecies types from human and environmental sources, J. Infect. Dis. 125:95–101.PubMedCrossRefGoogle Scholar
  123. 123.
    Collins, M. S., Edwards, A., Roby, R. E., Mehton, N. S., and Ladehoff, D., 1989, Pseudomonas immune globulin improves survival in experimental Pseudomonas aeruginosa bacteremic pneumonia, Antibiot. Chemother. 42:184–192.PubMedGoogle Scholar
  124. 124.
    Munster, A. M., Moran, K. T., Thupari, J., Allo, M., and Wunchurch, R. A., 1987, Prophylactic intravenous immunoglobulin replacement in high-risk burn patients, J. Burn Care Rehabil. 8:376–380.PubMedCrossRefGoogle Scholar
  125. 125.
    Waymack, J. P., Jenkins, M. E., Alexander, J. W., Warden, G. D., Miller, A. C., Carey, M., Ogle, C. K., and Kopcha, R. G., 1989, A prospective trial of prophylactic intravenous immune globulin for the prevention of infections in severely burned patients, Burns 15: 71–76.PubMedCrossRefGoogle Scholar
  126. 126.
    Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia, 1988, Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: A randomized, controlled clinical trial, N. Engl. J. Med. 319:902–907.CrossRefGoogle Scholar
  127. 127.
    Griffiths, H. Brennan, V., Lea, J., Bunch, C., Lee, M., and Chapel, H., 1989, Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors, Blood 73:366–368.PubMedGoogle Scholar
  128. 128.
    Rolfman, C. M., Lederman, H. M., Lavi, S., Stein, L. D., Levison, H., and Gelfand, E. W., 1985, Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease, Am. J. Med. 79:171–174.CrossRefGoogle Scholar
  129. 129.
    Chirico, G., Rondini, G., Plebani, A., Chiara, A., Massa, M., and Ugazio, A. G., 1987, Intravenous gammaglobulin therapy for prophylaxis of infection in high-risk neonates, J. Pediatr. 110:437–441.PubMedCrossRefGoogle Scholar
  130. 130.
    Clapp, D. W., Kliegman, R. M., Baley, J. E., Shenker, N., Kyllonen, K., Fanaroff, A. A., and Berger, M., 1989, Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: Report of a pilot study, J. Pediatr. 115: 973–978.PubMedCrossRefGoogle Scholar
  131. 131.
    Sakiel, S., Schiller, B., Buchowicz, J., and Kotkowska-Tomanek, E., 1983, Anti-Pseudomonas immunoglobulin: III. Preliminary clinical evaluation, Arch. Immunol. Ther. Exp. 31:517–521.Google Scholar
  132. 132.
    Meitert, T., Meitert, E., Szegli, G., and Peligrad, I., 1982, Therapeutic Pseudomonas aeruginosa antisera: Preparation, control and administration, Arch. Roum. Pathol. Exp. Microbiol. 41:115–121.PubMedGoogle Scholar
  133. 133.
    Bielory, L., Kemeny, D. M., Richards, D., and Lessof, M. H., 1990, IgG subclass antibody production in human serum sickness, J. Allergy Clin. Immunol. 85:573–577.PubMedCrossRefGoogle Scholar
  134. 134.
    Jones, C. E., Alexander, J. W., and Fisher, M., 1973, Clinical evaluation of Pseudomonas hyperimmune globulin, J. Surg. Res. 14:87–96.PubMedCrossRefGoogle Scholar
  135. 135.
    Holder, I. A., and Neely, A. N., 1987, Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: Post-sepsis treatment using Pseudomonas hyperimmune globulin and antibiotics alone and in combination, Serodiag. Immunother. 1:185–192.CrossRefGoogle Scholar
  136. 136.
    Martindale, J. J., Ganzinger, V., Steinmüller, W., Millendorfer, E A., Kollaritsch, H., and Wiedermann, G., 1988, Tolerability and immunogenicity of a polyvalent Pseudomonas aeruginosa extract vaccine in human volunteers, Zentralbi. Bakteriol. Hyg. A 268:376–385.Google Scholar
  137. 137.
    Martindale, J. J., Ganzinger, V., Steinmüller, W., Gaundera, E., Millendorfer, A., and Bachmayer, H., 1989, Pharmacokinetics of anti-Pseudomonas hyperimmunoglobulin after single intravenous administration in health subjects, Serodiag. Immunother Infect. Dis. 3: 93–99.CrossRefGoogle Scholar
  138. 138.
    Collins, M. S., and Roby, R. E., 1984, Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa, Am. J. Med. 76:168–174.PubMedCrossRefGoogle Scholar
  139. 139.
    Liu, P. V., Yoshii, S., and Hsieh, H., 1973, Exotoxins of Pseudomonas aeruginosa. II. Concentration, purification and characterization of exotoxin A, J. Infect. Dis. 128:514–519.PubMedCrossRefGoogle Scholar
  140. 140.
    Pollack, M., Callahan, L. T, III., and Taylor, N. S., 1976, Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: Evidence for in vivo toxin production during infections, Infect. Immun. 14:942–947.PubMedGoogle Scholar
  141. 141.
    Pollack, M., Taylor, N. S., and Callahan, L. T., III, 1977, Exotoxin production by clinical isolates of Pseudomonas aeruginosa, Infect. Immun. 15:776–780.PubMedGoogle Scholar
  142. 142.
    Bjorn, M. J., Vasil, M. L., Sadoff, J. C., and Iglewski, B. H., 1977, Incidence of exotoxin production by Pseudomonas species, Infect. Immun. 16:362–366.PubMedGoogle Scholar
  143. 143.
    Collins, M. S., Tsay, G. C., Hector, R. E., Roby, R. E., and Dorsey, J. H., 1987, Therapy of experimental Pseudomonas burn wound sepsis with ciprofloxacin and Pseudomonas immune globulin, Antibiot. Chemother. 39:222–232.PubMedGoogle Scholar
  144. 144.
    Collins, M. S., Hector, R. E., Edwards, A. A., Ladehoff, D. K., and Dorsey, J. H., 1987, Prophylaxis of gram-negative and gram-positive infections in rodents with three intravenous immunoglobulins and therapy of experimental polymicrobial burn wound sepsis with Pseudomonas immunoglobulin and ciprofloxacin, Infection 15:60–68.PubMedCrossRefGoogle Scholar
  145. 145.
    Salata, R. A., Lederman, M. M., Shlaes, D. M., Jacobs, M. R., Eckstein, E., Tweardy, D., Toossi, Z., Chmielewski, R., Marino, J., King, C. H., Graham, R. C., and Ellner, J. J., 1987, Diagnosis of nosocomial pneumonia in intubated, intensive care unit patients, Am. Rev. Respir. Dis. 135:426–432.PubMedGoogle Scholar
  146. 146.
    Chapel, H. M., and Bunch, C., 1987, Mechanisms of infection in chronic lymphocytic leukemia, Semin. Hematol. 24:291–296.PubMedGoogle Scholar
  147. 147.
    Rolfman, C. M., Levison, H., and Gefland, E. W, 1987, High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease, Lancet 1:1075–1077.CrossRefGoogle Scholar
  148. 148.
    Wingard, J. R., Dick, J., Charache, P, and Saral, R., 1986, Antibiotic-resistant bacteria in surveillance stool cultures of patients with prolonged neutropenia, Antimicrob. Agents Chemother. 30:435–439.PubMedCrossRefGoogle Scholar
  149. 149.
    Dick, J. D., Shull, V., Karp, J. E., and Valentine, J., 1988, Bacterial and host factors affecting Pseudomonas aeruginosa colonization versus bacteremia in granulocytopenic patients, Eur. J. Clin. Oncol. 24:S47–S54.Google Scholar
  150. 150.
    Hilf, M., Yu, V. L., Sharp, J., Zuravleff, J. J., Korvick, J. A., and Muder, R. R., 1989, Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients, Am. J. Med. 87:540–546.PubMedCrossRefGoogle Scholar
  151. 151.
    Neely, A. N., and Holder, I. A., 1987, Use of passive immunotherapy in the treatment of experimental Pseudomonas aeruginosa infections in burns, Antibiot. Chemother. 39:26–40.PubMedGoogle Scholar
  152. 152.
    Pennington, J. E., Pier, G. B., and Small, G. J., 1986, Efficacy of intravenous immune globulin for treatment of Pseudomonas aeruginosa pneumonia, J. Grit. Care 1:4–10.CrossRefGoogle Scholar
  153. 153.
    Pennington, J. E., Small, G. J., Lostrom, M. E., and Pier, G. B., 1986, Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia, Infect. Immun. 54:239–244.PubMedGoogle Scholar
  154. 154.
    Pennington, J. E., and Small, G. J., 1987, Passive immune therapy for experimental Pseudomonas aeruginosa pneumonia in the neutropenic host, J. Infect. Dis. 155:973–978.PubMedCrossRefGoogle Scholar
  155. 155.
    Collins, M. S., Mehton, N. S., Edwards, A. A., and Ladehoff, D. K., 1989, Der therapieeffekt von immunoglobulin bei der experimentellen bakteriellen pneumonie durch Pseudomonas aeruginosa korreliert mit der in vitro opsonin-aktivität und der in vivo neutralisation von exotoxin A, Intensivrned 26:97–101.Google Scholar
  156. 156.
    Jones, R. J., Rae, E. A., and Gupta, J. L., 1980, Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients, Lancet ií:1263–1265.CrossRefGoogle Scholar
  157. 157.
    Jones, R. J., 1979, Antibody responses of burned patients immunized with a polyvalent Pseudomonas vaccine, J. Hyg. 82:453–462.CrossRefGoogle Scholar
  158. 158.
    Hunt, J. I., and Purdue, G. E, 1988, A clinical trial of IV tetravalent hyperimmune Pseudomonas globulin G in burned patients, J. Trauma 28:146–151.PubMedCrossRefGoogle Scholar
  159. 159.
    Kistler, D., Piert, M., and Hettich, R., 1989, Use of Pseudomonas hyper-immunoglobulin to treat septic shock in burn cases, J Burn Care Rehabil. 10:321–326.PubMedCrossRefGoogle Scholar
  160. 160.
    Van Wye, J. E., Collins, M. S., Baylor, M., Pennington, J. E., Hsu, Y. P, Sampanvejsopa, V, and Moss, R. B., 1990, Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis, Pediatr. Pulmonol. 9:7–18.PubMedCrossRefGoogle Scholar
  161. 161.
    Liu, P. V, and Wang, S., 1990, Three new major somatic antigens of Pseudomonas aeruginosa, J. Clin. Microbial. 28:922–925.Google Scholar
  162. 162.
    Wilkinson, S. G., 1983, Composition and structure of lipopolysaccharides from Pseudomonas aeruginosa, Rev. Infect. Dis. 5:S941–S949.PubMedCrossRefGoogle Scholar
  163. 163.
    Dunn, D. L., Ewald, D. C., Chandan, N., and Cerra, E B., 1986, Immunotherapy of gram-negative bacterial sepsis: A single murine monoclonal antibody provides cross-genera protection, Arch. Surg. 121:58–62.PubMedCrossRefGoogle Scholar
  164. 164.
    Aldridge, M. C., Chadwick, S. J. D., Cheslyn-Curtis, S., Rapson, N., and Dudley, H. A. E, 1987, Antibody to endotoxin core glycolipid reverses reticuloendothelial system depression in an animal model of severe sepsis and surgical injury, J. Trauma 27:1166–1172.PubMedCrossRefGoogle Scholar
  165. 165.
    Baumgartner, J. D., O’Brien, T. X., Kirkland, T. N., Glauser, M. P., and Ziegler, E. J., 1987, Demonstration of cross-reactive antibodies to smooth gram-negative bacteria in antiserum to Escherichia coli J5, J. Infect. Dis. 156:136–143.PubMedCrossRefGoogle Scholar
  166. 166.
    Bogard, W. C., Jr., Dunn, D. L., Abernethy, K., Kilgarriff, C., and Kung, P. C., 1987, Isolation and characterization of murine monoclonal antibodies specific for gram-negative bacterial lipopolysaccharide: Association of cross-genus reactivity with lipid A specificity, Infect. Immun. 55:899–908.PubMedGoogle Scholar
  167. 167.
    Pollack, M., Raubitschek, A. A., and Larrick, J. W, 1987, Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides, J. Clin. Invest. 79:1421–1430.PubMedCrossRefGoogle Scholar
  168. 168.
    Appelmelk, B.J., Verweij-vanVught, A. M. J. J., Maaskant, J. J., Schouten, W. E, De Jonge, A. J. R., Thijs, L. G., and Maclaren, D. M., 1988, Production and characterization of mouse monoclonal antibodies reacting with the lipopolysaccharide core region of gram-negative bacilli, J. Med. Microbiol. 26:107–114.PubMedCrossRefGoogle Scholar
  169. 169.
    Aydintug, M. K., Inzana, T. J., Letonja, T., Davis, W. C., and Corbeil, L. B., 1989, Cross-reactivity of monoclonal antibodies to Escherichia coli J5 with heterologous gram-negative bacteria and extracted lipopolysaccharides, J. Infect. Dis. 160:846–857.PubMedCrossRefGoogle Scholar
  170. 170.
    Priest, B. P., Brinson, D. N., Schroeder, D. A., and Dunn, D. L., 1989, Treatment of experimental gram-negative bacterial sepsis with murine monoclonal antibodies directed against lipopolysaccharide, Surgery 106:147–155.PubMedGoogle Scholar
  171. 171.
    Pollack, M., Huang, A. I., Prescott, R. K., Young, L. S., Hunter, K. W, Cruess, D. E, and Tsai, C. M., 1983, Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core, J. Clin. Invest. 72:1874–1881.PubMedCrossRefGoogle Scholar
  172. 172.
    Ziegler, E. J., McCutchan, J. A., Douglas, H., and Braude, H., 1975, Prevention of lethal Pseudomonas bacteremia with epimerase-deficient E. coli antiserum, Trans. Assoc. Am. Physicians 88:101–108.PubMedGoogle Scholar
  173. 173.
    Martinez, D., and Callahan, L. T., III,1985, Prophylaxis of Pseudomonas aeruginosa infections in leukopenic mice by a combination of active and passive immunization, Eur. J. Clin. Microbiol. 4:186–189.PubMedCrossRefGoogle Scholar
  174. 174.
    Ziegler, E. J., McCutchan, A., Fierer, J., Glauser, M. E, Sadoff, J. C., Douglas, H., and Braude, A. I., 1982, Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli, N. Engl. J. Med. 307:1225–1230.PubMedCrossRefGoogle Scholar
  175. 175.
    Baumgartner, J. D., Heumann, D., Calandra, T., and Glauser, M. E, 1991, Antibodies to lipopolysaccharides after immunization of humans with the rough mutant of Escherichia coli J5, J. Infect. Dis. 163:769–772.PubMedCrossRefGoogle Scholar
  176. 176.
    Teng, N. N. H., Kaplan, H. S., Hebert, J. M., Moore, C., Douglas, H., Wunderlich, A., and Braude, A. I. 1985, Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies, Proc. Natl. Acad. Sci. USA 82:1790–1794.PubMedCrossRefGoogle Scholar
  177. 177.
    Ziegler, E. J., Fisher, C. J., Jr., Sprung, C. L., Straube, R. C., Sadoff, J. C., Foulke, G. E., Wortel, C. H., Fink, M. P, Dellinger, R. E, Teng, N. N. H., Allen, E., Berger, H. J., Knatterud, G. L., LoBuglio, A. E, Smith, C. R., and the HA-lA Sepsis Study Group, 1991, Treatment of gram-negative bacteremia and septic shock with HA-lA human monoclonal antibody against endotoxin, N. Engl. J. Med. 324:429–436.PubMedCrossRefGoogle Scholar
  178. 178.
    Ng, A-K., Chen, C-L. H., Chang, C-M., and Nowotany, A., 1976, Relationship of structure to function in bacterial endotoxins: Serologically cross-reactive components and their effect on protection of mice against some gram-negative infections, J. Gen. Microbiol. 94: 107–116.PubMedCrossRefGoogle Scholar
  179. 179.
    Pennington, J. E., and Menkes, E., 1981, Type-specific versus cross-protective vaccination for gram negative bacterial pneumonia, J. Infect. Dis. 144:599–603.PubMedCrossRefGoogle Scholar
  180. 180.
    Cryz, S. J., Jr., Merdow, P. M., Hirer, E., and Germancer, R., 1985, Protection against fatal Pseudomonas aeruginosa sepsis by immunization with smooth and rough lipopolysaccharides, Eur. J. Clin. Microbiol. 4:180–185.PubMedCrossRefGoogle Scholar
  181. 181.
    Calandra, T., Glauser, M. P, Schellekens, J., Verhoef, J., and the Swiss-Dutch J5 Study Group, 1988, Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial,) Infect. Dis. 158:312–319.CrossRefGoogle Scholar
  182. 182.
    Hancock, R. E. W, Wieczorek, A. A., Mutharia, L. M., and Poole, K., 1982, Monoclonal antibodies against Pseudomonas aeruginosa outer membrane antigens: Isolation and characterization, Infect. Immun. 37:166–171.PubMedGoogle Scholar
  183. 183.
    Hancock, R. E. W, Mutharia, L. M., and Mouat, E. C. A., 1985, Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F, Eur. J. Clin. Microbiol. 4:224–227.PubMedCrossRefGoogle Scholar
  184. 184.
    Battershill, J. L., Speert, D. E, and Hancock, R. E. W, 1987, Use of monoclonal antibodies to protein F of Pseudomonas aeruginosa as opsonins for phagocytosis by macrophages, Infect. Immun. 55:2531–2533.PubMedGoogle Scholar
  185. 185.
    Moon, M. M., Hazlett, L. D., Hancock, R. E. W., Berk, R. S., and Barrett, R., 1988, Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection, Invest. Opthalmol. Vis. Sci. 29:1277–1284.Google Scholar
  186. 186.
    Finke, M., Muth, G., Reichhelm, T., Thoma, M., Duchêne, M., Hungerer, K.-D., Domdey, H., and vonSpecht, B.-U., 1991, Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies, Infect. Immun. 59:1251–1254.PubMedGoogle Scholar
  187. 187.
    Sokol, P. A., and Woods, D. E., 1986, Monoclonal antibodies to Pseudomonas aeruginosa ferripyochelin-binding protein, Infect. Immun. 53:621–627.PubMedGoogle Scholar
  188. 188.
    Saiman, L. Sadoff, J., and Prince, A., 1989, Cross-reactivity of Pseudomonas aeruginosa antipilin monoclonal antibodies with hetrogenous strains of P. aeruginosa and Pseudomonas cepacia, Infect. Immun. 57:2764–2770.PubMedGoogle Scholar
  189. 189.
    Doig, E, Sastry, P. A., Hodges, R. S., Lee, K. K., Paranchych, W, and Irvin, R. I., 1990, Inhibition of pilus-mediated adhesion of Pseudomonas aeruginosa to human buccal epithe-lial cells by monoclonal antibodies directed against pili, Infect. Immun. 58:124–130.PubMedGoogle Scholar
  190. 190.
    Rosok, M. J., Stebbins, M. R., Connelly, K., Lostrom, M. E., and Siadak, A. W, 1990, Generation and characterization of murine antiflagellum monoclonal antibodies that are protective against lethal challenge with Pseudomonas aeruginosa, Infect. Immun. 58:3819–3828.PubMedGoogle Scholar
  191. 191.
    Ochi, H., Ohtsuka, H., Yokuta, S. I., Uerzumi, I., Terashima, M., Irie, K., and Noguchi, H., 1991, Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa, Infect. Immun. 59: 550–554.PubMedGoogle Scholar
  192. 192.
    Irvin, R. T., and Ceri, H., 1985, Immunochemical examination of the Pseudomonas aeruginosa glycocalyx: A monoclonal antibody which recognizes L-guluronic acid residues of alginic acid, Can. J. Microbiol. 31:268–275.PubMedCrossRefGoogle Scholar
  193. 193.
    Terashima, M., Uezumi, I., Tomio, T., Kato, M., Irie, K., Okuda, T., Yokota, S., and Noguchi, H., 1991, A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide, Infect. Immun. 59:1–6.PubMedGoogle Scholar
  194. 194.
    Sawada, S., Suzuki, M., Kawamura, T., Fujinaga, S., Masuho, Y., and Tomibe, K., 1984, Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins, J. Infect. Dis. 150: 570–576.PubMedCrossRefGoogle Scholar
  195. 195.
    Barclay, G. R., Yap, P. L., McClelland, D. B. L., Jones, R. J., Roe, E. A., McCann, M. C., Micklem, L. R., and James, K., 1986, Characterization of mouse monoclonal antibodies produced by immunization with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine,,. Med. Microbiol. 21:87–90.CrossRefGoogle Scholar
  196. 196.
    Pennington, J. E., Small, G. J., Lostrom, M. E., and Pier, G. B., 1986, Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia, Infect. Immun. 54:239–244.PubMedGoogle Scholar
  197. 197.
    Stoll, B. J., Pollock, M., Young, L. S., Koles, N., Gascon, R., and Pier, G. B., 1986, Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide, Infect. Immun. 53:656–662.PubMedGoogle Scholar
  198. 198.
    Suzuki, H., Okubo, Y., Moriyami, M., Susaki, M., Matsumoto, Y., and Hozumi, T., 1987, Human monoclonal antibodies to Pseudomonas aeruginosa, Microbiol. Immunol. 31:959–966.PubMedGoogle Scholar
  199. 199.
    Zweerink, H. J., Gammon, M. C., Hutchison, C. E, Jackson, J. J., Lombardo, D., Miner, K. M., Puckett, J. M., Sewell, T. J., and Sigal, N. H., 1988, Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa, Infect. Immun. 56:1873–1879.PubMedGoogle Scholar
  200. 200.
    Hector, R. E, Collins, M. S., and Pennington, J. E., 1989, Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody, J. Infect. Dis. 160:483–489.PubMedCrossRefGoogle Scholar
  201. 201.
    Lang, A. B., Hirer, E., Larrick, J. W, and Cryz, S. J., Jr., 1989, Isolation and characterization of a human monoclonal antibody that recognizes epitopes shared by Pseudomonas aeruginosa immunotype 1, 3, 4 and 6 lipopolysaccharides, Infect. Immun. 57:3851–3855.PubMedGoogle Scholar
  202. 202.
    Yoshida, K., Kimura, E, Uchida, K., Kawaharajo, K., Koizumi, N., Nakajima, S., and Nagaoka, K., 1989, Production and some properties of monoclonal antibodies against serotype strains of Pseudomonas aeruginosa, J. Pharmacobiol-Dyn. 12:398–404.CrossRefGoogle Scholar
  203. 203.
    Husson, M. O., Mielcarek, C., Gavini, E, Caron, C., Izard, D., and Leclerc, H., 1989, Isolation and characterization of monoclonal antibodies against alkaline phosphatese of Pseudomonas aeruginosa, J. Clin. Microbiol. 27:1115–1118.PubMedGoogle Scholar
  204. 204.
    Lagacé, J., and Fréchette, M., 1991, Four epitopes of Pseudomonas aeruginosa elastase defined by monoclonal antibodies, Infect. Immun. 59:712–715.PubMedGoogle Scholar
  205. 205.
    Galloway, D. R., Hedstrom, R. C., and Pavlovskis, O. R., 1984, Production and characterization of monoclonal antibodies to exotoxin A from Pseudomonas aeruginosa, Infect. Immun. 44:262–267.PubMedGoogle Scholar
  206. 206.
    Chia, J. K. S., Pollack, M., Avigar, D., and Steinbach, S., 1986, Functionally distinct monoclonal antibodies reactive with enzymatically active and binding domains of Pseudomonas aeruginosa toxin A, Infect. Immun. 52:756–762.PubMedGoogle Scholar
  207. 207.
    Woods, D. E., and Que, J. V., 1987, Purification of Pseudomonas aeruginosa exoenzyme S, Infect. Immun. 55:579–586.PubMedGoogle Scholar
  208. 208.
    Venezia, N. D., Calmels, S., and Bartsch, H., 1991, Production of polyclonal and monoclonal antibodies for specific detection of nitrosation-proficient denifrifying bacteria in biological fluids, Biochem. Biophys. Res. Commun. 176:262–268.PubMedCrossRefGoogle Scholar
  209. 209.
    Allan, B., Linseman, M., MacDonald, L. A., Lam, J. S., and Kropinski, A. M., 1988, Heat shock response of Pseudomonas aeruginosa, J. Bacterial. 170:3668–3674.Google Scholar
  210. 210.
    Norris, S. A., and Sciortino, C. V, 1988, Monoclonal antibody to an aminoglycosideresistance factor from Pseudomonas aeruginosa, J. Infect. Dis. 158:1324–1328.PubMedCrossRefGoogle Scholar
  211. 211.
    Murakami, K., and Yoshida, T., 1985, Monoclonal antibodies against species-specific cephalosporinase of Pseudomonas aeruginosa, Eur. J. Biochem. 146:693–697.PubMedCrossRefGoogle Scholar
  212. 212.
    Sawada, S., Kawamura, T., Masuho, Y., and Tomibe, K., 1985, A new common polysaccharide antigen of strains of Pseudomonas aeruginosa detected with a monoclonal antibody, J. Infect. Dis. 152:1290–1299.PubMedCrossRefGoogle Scholar
  213. 213.
    Lam, M. Y. C., McGroarty, E. J., Kropinski, A. M., MacDonald, L. A., Pedersen, S. S., Hoiby, N., and Lam, J. S., 1989, Occurrence of a common lipopolysaccharide antigen in standard and clinical strains of Pseudomonas aeruginosa, J Clin. Microbiol. 27:962–967.PubMedGoogle Scholar
  214. 214.
    Rivera, M., and McGroarty, E. J., 1989, Analysis of a common-antigen lipopolysaccharide from Pseudomonas aeruginosa, J. Bacteriol. 171:2244–2248.PubMedGoogle Scholar
  215. 215.
    Yokota, S., Ochi, H., Ohtsuka, H., Kato, M., and Noguchi, H., 1989, Heterogeneity of the L-rhamnose residue in the outer core of Pseudomonas aeruginosa lipopolysaccharide, characterized by using human monoclonal antibodies, Infect. Immun. 57:1691–1696.PubMedGoogle Scholar
  216. 216.
    Yokota, S., Ochi, H., Uezumi, I., Ohtsuka, H., Irie, K., and Noguchi, H., 1990, N-acetylL-galactosaminuronic acid as an epitope common to the O-polysaccharides of Pseudomonas aeruginosa A and H (Homma) recognized by a protective human monoclonal antibody, Eur. J. Biochem. 192:109–113.PubMedCrossRefGoogle Scholar
  217. 217.
    Yokota, S. I., Kaya, S., Araki, Y., Ito, E., Kawamura, T., and Sawada, S., 1990, Occurrence of D-rhamnan as the common antigen reactive against monoclonal antibody E87 in Pseudomonas aeruginosa IFO 3080 and other strains, J. Bacteriol. 172:6162–6164.PubMedGoogle Scholar
  218. 218.
    Collins, H. H., Cross, A. S., Dobek, A., Opal, S. M., McClain, J. B., and Sadoff, J. C., 1989, Oral ciprofloxacin and a monoclonal antibody to lipopolysaccharide protect leukopenic rats from lethal infection with Pseudomonas aeruginosa, J. Infect. Dis. 159:1073–1082.PubMedCrossRefGoogle Scholar
  219. 219.
    Pier, G. B., Thomas, D., Small, G., Siadak, A., and Zweerink, H., 1989, In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide, Infect. Immun. 57:174–179.PubMedGoogle Scholar
  220. 220.
    Sawada, S., Kawamura, T., Masuho, Y., and Tomibe, K., 1985, Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: A possible candidate as an immunotherapeutic agent for infections with P aeruginosa, J. Infect. Dis. 152:965–970.PubMedCrossRefGoogle Scholar
  221. 221.
    Sawada, S., Kawamura, T., and Masuho, Y., 1987, Immunoprotective human monoclonal antibodies against five major serotypes of Pseudomonas aeruginosa, J. Gen. Microbiol. 133: 3581–3590.PubMedGoogle Scholar
  222. 222.
    Sawada, S., Kawamura, T., Masuho, Y., Iyobe, S., and Hashimoto, H., 1989, Protection against experimental Pseudomonas infection with O antigen-specific human monoclonal antibodies, Antibiot. Chemother 42:210–217.PubMedGoogle Scholar
  223. 223.
    Zweerink, H. J., Gammon, M. C., Hutchinson, C. E, Jackson, J. J., Pier, G. B., Puckett, J. M., Sewell, T. A., and Sigal, N. H., 1988, X-linked immunodeficient mice as a model for testing the protective efficacy of monoclonal antibodies against Pseudomonas aeruginosa, Infect. Immun. 56:1209–1214.PubMedGoogle Scholar
  224. 224.
    Zweerink, H. J., Detolla, L. J., Gammon, M. C., Hutchinson, C. E, Puckett, J. M., and Sigal, N. H., 1990, A human monoclonal antibody that protects mice against Pseudomonas-induced pneumonia, J. Infect. Dis. 162:254–257.PubMedCrossRefGoogle Scholar
  225. 225.
    Collins, M. S., Edwards, A. A., Ladehoff, D., and Mehton, N. S., 1989, Activity of antilipopolysaccharide human 1gM monoclonal antibodies in the treatment of Pseudomonas aeruginosa —Staphylococcus aureus polymicrobic cellulitis, Serodiag. Immunother. Infect. Dis. 3: 225–230.CrossRefGoogle Scholar
  226. 226.
    Saravolatz, L. D., Markowitz, N., Collins, M. S., Bogdanoff, D., and Pennington, J. E., 1991, Safety, pharmacokinetics and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and non-septic patients, J. Infect. Dis., in press.Google Scholar
  227. 227.
    Collins, M. S., Ladehoff, D. K., Mehton, N. S., and Noonan, J. S., 1990, Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa, FEMS Microbiol. Immunol. 64:263–268.CrossRefGoogle Scholar
  228. 228.
    Collins, M. S., Ladehoff, D., and Mehton, N. S., 1991, Therapy of established experimental Pseudomonas aeruginosa infections with oral ciprofloxacin and five human monoclonal antibodies against lipopolysaccharide antigens, Antibiot. Chemother. in press.Google Scholar
  229. 229.
    Gearing, A. J. H., Leung, H., Bird, C. R., and Thorpe, R., 1989, Presence of the inflammatory cytokines IL-1, TNF and IL-6 in preparations of monoclonal antibodies, Hybridoma 8:361–367.PubMedCrossRefGoogle Scholar
  230. 230.
    Bartal, A. H., Feit, C., Erlandson, R., and Hirshaut, Y., 1982, The presence of viral particles in hybridoma clones secreting monoclonal antibodies, N. Engl. J. Med. 306:1423.PubMedGoogle Scholar
  231. 231.
    Weisfuse, I. B., Graham, D. J., Will, M., Parkinson, D., Snydman, D. R., Atkins, M., Karron, R. A., Feinstone, S., Rayner, A. A., Fisher, R. I., Mills, B. J., Dutcher, J. P., Weiss, G. R., Glover, A., Kuritsky, J. N., and Hadler, S. C., 1990, An outbreak of hepatitis A among cancer patients treated with interleukin-2 and lymphokine-activated killer cells, J. Infect. Dis. 161: 647–652.PubMedCrossRefGoogle Scholar
  232. 232.
    Sumazaki, R., Fujita, T., Kabashima, T., Nishikaku, E, Koyama, A., Shibaski, M., and Takita, H., 1986, Monoclonal antibody against bacterial lipopolysaccharide cross-reacts with DNA-histone, Clin. Exp. Immunol. 66:103–110.PubMedGoogle Scholar
  233. 233.
    Woods, J. P., Black, J. R., Barrit, D. S., Connell, T. D., and Cannon, J. G., 1987, Resistance to meningococcemia apparently conferred by anti-H.8 monoclonal antibody is due to contaminating endotoxin and not to specific immunoprotection, Infect. Immun. 55:1927–1928.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Michael S. Collins
    • 1
  1. 1.Miles Pharmaceutical DivisionMiles Inc.West HavenUSA

Personalised recommendations